Quality of life in patients with venous thromboembolism and atrial fibrillation treated with coumarin anticoagulants
2015 (English)In: Thrombosis Research, ISSN 0049-3848, E-ISSN 1879-2472, Vol. 136, no 1, 69-75 p.Article in journal (Refereed) Published
Introduction: Little is known about the overall quality of life (QOL) in patients newly diagnosed with venous thromboembolism (VTE) and atrial fibrillation (AF). We studied QOL in patients with VTE and AF immediately after the start of anticoagulant therapy, and after three months of treatment. Furthermore we identified whether QOL was affected by age, gender and nationality. Materials and Methods: The European pharmacogenetics of anticoagulant therapy (EU-PACT) study was a multicentre, randomized controlled trial of patients aged > 18 years diagnosed with VTE or AF. QOL was assessed using EuroQol 5 dimensions (EQ-5D) questionnaires. Results: The EQ-5D questionnaires were completed by 187 patients with VTE and 660 patients with AF. The QOL in patients diagnosed with VTE or AF was significantly impaired, however, during a 3 months treatment period, patients experienced an improvement (p < 0.05). The QOL in patients diagnosed with VTE improved with increasing age, with similar effects seen in men and women. Men and women diagnosed with AF differed in QOL (respectively 0.84 and 0.74, p < 0.05), and QOL decreased with age. Comparison between countries showed significant differences in the EQ-Index score at follow-up of patients with VTE, and in both EQ-Index score and EQ-VAS of patients with AF. Conclusions: The QOL in patients with VTE and AF is strongly reduced directly after the start of anticoagulant treatment, but improves within 3 months. Moreover, QOL is influenced by demographic and disease-specific variables. These findings provide useful information for future cost-effectiveness studies.
Place, publisher, year, edition, pages
2015. Vol. 136, no 1, 69-75 p.
Age, Atrial fibrillation, Nationality, Quality of life, Venous thromboembolism
IdentifiersURN: urn:nbn:se:uu:diva-265944DOI: 10.1016/j.thromres.2015.04.026ISI: 000361899300013PubMedID: 25956287OAI: oai:DiVA.org:uu-265944DiVA: diva2:866924
FunderEU, FP7, Seventh Framework Programme, F2 2009 223062GlaxoSmithKline (GSK)Swedish Research CouncilSwedish Heart Lung Foundation